{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T10:03:49Z","timestamp":1793786629858,"version":"4.6.1"},"reference-count":41,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mantle cell lymphoma (MCL) is clinically characterized by its heterogenous behavior with courses ranging from indolent cases that do not require therapy for years to highly aggressive MCL with very limited prognosis. The development and implementation of new targeted and immunotherapeutic approaches have already improved therapeutic options especially for refractory or relapsed disease. Nevertheless, to further optimize MCL treatment, early identification of individual risk profile and risk\u2010adapted, patient\u2010tailored choice of therapeutic strategy needs to be prospectively incorporated in clinical patient management. This review summarizes the current knowledge and standard of care regarding biology and clinical management of MCL, highlighting the implementation of new therapeutic approaches especially targeting the immune system.<\/jats:p>","DOI":"10.1002\/hon.3149","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T17:16:10Z","timestamp":1686330970000},"page":"36-42","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Mantle cell lymphoma\u2014Update on molecular biology, prognostication and treatment approaches"],"prefix":"10.1002","volume":"41","author":[{"given":"Elisabeth","family":"Silkenstedt","sequence":"first","affiliation":[{"name":"Department of Medicine III LMU University Hospital  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Medicine III LMU University Hospital  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx223"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11096"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015851"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.63.8387"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1753"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01780"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01294"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/hs9.0000000000000712"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci61272"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-09-3419"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005289"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001350"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-797019"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-779736"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-018-0022-5"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1314608110"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci153283"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-230250"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.19.6121"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1701769"},{"key":"e_1_2_8_25_1","article-title":"Efficacy and safety of ibrutinib combined with standard first\u2010line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL network","author":"Dreyling MDJ","year":"2022","journal-title":"ASH Annu Meet"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02321"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1701769"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110289"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1200920"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30685-5"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(16)30185-5"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61763-2"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.17_suppl.lba7502"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1306220"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00438-6"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)33108-2"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014162"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00224-5"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1715519"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-859769"},{"key":"e_1_2_8_41_1","article-title":"Three\u2010year follow\u2010up of KTE\u2010X19 in patients with relapsed\/refractory mantle cell lymphoma, including high\u2010risk subgroups, in the ZUMA\u20102 study","author":"Wang M","year":"2022","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157777"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.3149","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T02:32:36Z","timestamp":1692412356000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.3149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":41,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1002\/hon.3149"],"URL":"https:\/\/doi.org\/10.1002\/hon.3149","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"2023-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}